Proteomics International Laboratories Ltd (ASX:PIQ)
Australia
· Delayed Price · Currency is AUD 0.325
-0.005 (-1.52%)
At close: Mar 6, 2026
ASX:PIQ Revenue
Proteomics International Laboratories had revenue of 729.98K AUD in the half year ending December 31, 2025, with 18.12% growth. This brings the company's revenue in the last twelve months to 3.21M, down -8.11% year-over-year. In the fiscal year ending June 30, 2025, Proteomics International Laboratories had annual revenue of 3.31M with 1.34% growth.
Revenue (ttm)
3.21M
Revenue Growth
-8.11%
P/S Ratio
16.75
Revenue / Employee
n/a
Employees
n/a
Market Cap
53.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.31M | 43.87K | 1.34% |
| Jun 30, 2024 | 3.27M | 87.53K | 2.75% |
| Jun 30, 2023 | 3.18M | -249.17K | -7.26% |
| Jun 30, 2022 | 3.43M | 694.47K | 25.38% |
| Jun 30, 2021 | 2.74M | 6.89K | 0.25% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Entropy Neurodynamics | 1.58M |
| Amplia Therapeutics | 5.01M |
| Neurizon Therapeutics | 5.98M |
| EZZ Life Science Holdings | 61.40M |
| Prescient Therapeutics | 4.27M |
| Avecho Biotechnology | 1.24M |
| Radiopharm Theranostics | 16.28M |
| Imugene | 3.94M |